Outcomes study for the XL1 distraction enterogenesis device to improve nutrient absorption in short bowel syndrome
Official title: Outcomes study for the XL1 distraction enterogenesis device to improve nutrient absorption in short bowel syndrome patients
Funded at Eclipse Enterogenesis, INC. · NIH-11416687 · Data updated 2026-11-12
A study testing a novel XL1 device to help people with short bowel syndrome absorb nutrients better, potentially reducing reliance on intravenous nutrition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eclipse Enterogenesis, INC. NIH-funded |
| Lab location | 1 site (Menlo Park, United States) |
| Project start | July 12, 2021 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $860,948 |
| NIH project number | 5R44DK127658-05 |
| Project ID | NIH-11416687 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pediatric and adult SBS patients who have significant small intestine loss and are candidates for novel treatment options.
✕Less likely to help
SBS patients whose anatomy or health status excludes device use or who cannot tolerate the procedure.
What this research studies
Short bowel syndrome leaves patients unable to absorb enough nutrients due to loss of small intestine. This project aims to test the XL1 distraction enterogenesis device to promote intestinal adaptation and nutrient absorption in SBS patients. Researchers will monitor safety and how well the device improves absorption, with follow-up on health outcomes and treatment costs. The work involves clinical evaluation in pediatric and adult SBS patients to determine real-world benefits and risks of this new approach.
Why it matters
Potential benefit: If successful, patients could experience better nutrient absorption and less dependence on IV nutrition and related complications.
How similar studies have gone: Previous clinical studies in SBS have shown the potential of novel devices to aid intestinal adaptation, but this exact XL1 approach is exploratory.
Where this research is happening
-
Eclipse Enterogenesis, INC.
Menlo Park, United States Active
Researchers
- Principal investigator: Bessette, Andre — Eclipse Enterogenesis, INC.
- Study coordinator: Bessette, Andre
Related research
Other NIH-funded projects on the same topics.
-
XL1 device to gently lengthen the intestine and improve absorption for short bowel syndrome
A small implantable device called XL1 aims to gently stretch the remaining intestine to help children and adults with short bowel syndrome absorb more nutrients naturally.
-
Lengthening the intestine to help patients with Short Bowel Syndrome
This study is exploring a new way to help people with Short Bowel Syndrome by gently stretching their remaining small intestine, which could help them absorb more nutrients and reduce the need for expensive treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.